Metabolism of ADB-FUBIATA in zebrafish and pooled human liver microsomes investigated by liquid chromatography-high-resolution mass spectrometry.
Rapid Commun Mass Spectrom
; 38(9): e9730, 2024 May 15.
Article
in En
| MEDLINE
| ID: mdl-38456249
ABSTRACT
RATIONALE ADB-FUBIATA is one of the most recently identified new psychoactive substance (NPS) of synthetic cannabinoids. The co-use of in vitro (human liver microsomes) and in vivo (zebrafish) models offers abundant metabolites and may give a deep insight into the metabolism of NPS. METHODS:
In vivo and in vitro metabolic studies of new synthetic cannabinoid ADB-FUBIATA were carried out using zebrafish and pooled human liver microsome models. Metabilites were structurally characterized by liquid chromatography-high-resolution mass spectrometry.RESULTS:
In total, 18 metabolites were discovered and identified in the pooled human liver microsomes and zebrafish, including seventeen phase I metabolites and one phase II metabolite. The main metabolic pathways of ADB-FUBIATA were hydroxylation, dehydrogenation, N-dealkylation, amide hydrolysis, glucuronidation, and combination thereof.CONCLUSION:
Hydroxylated metabolites can be recommended as metabolic markers for ADB-FUBIATA because of the structural characteristics and high intensity. These metabolism characteristics of ADB-FUBIATA were useful for its further forensic or clinical related investigations.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Perciformes
/
Cannabinoids
Limits:
Animals
/
Humans
Language:
En
Journal:
Rapid Commun Mass Spectrom
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
Reino Unido